首页MOLN • NASDAQ
add
Molecular Partners AG
市场资讯
财务信息
损益表
收入
净收入
| (CHF) | 2025年6月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 399.40万 | -10.05% |
净收入 | -2039.80万 | -35.25% |
净利润率 | — | — |
每股收益 | -0.56 | — |
息税折旧摊销前利润 | -1414.70万 | 7.98% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (CHF) | 2025年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 1.14亿 | -28.05% |
总资产 | 1.24亿 | -27.17% |
负债总额 | 1759.00万 | 16.89% |
权益总额 | 1.07亿 | — |
发行在外的股份 | 3739.24万 | — |
市净率 | 1.32 | — |
资产回报率 | -27.70% | — |
资本回报率 | -30.77% | — |
现金流
现金净变动
| (CHF) | 2025年6月info | 年同比变化 |
|---|---|---|
净收入 | -2039.80万 | -35.25% |
来自运营的现金 | -1310.00万 | 16.68% |
投资现金 | 1497.00万 | 13.85% |
融资现金 | -24.30万 | 8.99% |
现金净变动 | 60.30万 | 122.68% |
自由现金流 | -361.00万 | 63.16% |
简介
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
成立时间
2004
员工数量
153
